AzTrials
AzTrials

Intensive Care Unit ICUBRILSNCT06697340

Braden Pressure Ulcer Scale for Prediction of the Intensive Care Length of Stay

An observational study of Intensive Care Unit ICU and Length of ICU Stay, run by Ankara City Hospital Bilkent at 1 site in Turkey (Türkiye).

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The aim of this study is to predict the length of intensive care unit stay of patients treated in a tertiary general intensive care unit with the help of the Braden risk assesment scale, which is used to predict the risk of pressure ulcers. Read more about this study

Who is it for?
Ages 18 years and older
How many people
11,000 participants
Where
1 siteTurkey (Türkiye)
Study dates
1 Jan 2025to 31 May 2025
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Medical and surgical intensive care patients admitted to the tertiary general intensive care unit of Ankara Bilkent City Hospital

Who may be able to join

  • Patients older than 18 years
  • Patients treated in intensive care
  • Patients treated with diagnoses other than Covid-19
  • Patients without missing data in the hospital electronic data system
  • Patients hospitalized for more than 24 hours

Who cannot join

  • Patients younger than 18 years
  • Patients treated for Covid-19 disease
  • Patients with missing data in the hospital electronic data system
  • Patients hospitalized for less than 24 hours

Trial locations and contacts

1 site in 1 country.

Turkey (Türkiye)1 site
  • Ankara Bilkent City Hospital

    Ankara

Other trials in Turkey (Türkiye)

About this study

Official title: The Effect of the Braden Pressure Ulcer Scale on the Prediction of Intensive Care Unit Length of Stay

The aim of this study is to predict the length of intensive care unit stay of patients treated in a tertiary general intensive care unit with the help of the Braden risk assesment scale, which is used to predict the risk of pressure ulcers. The main question it aims to answer is:

  • Does high Braden scales predict the long lenght of stay? Braden scales of patients admitted to the intensive care unit were recorded every day.
Read the detailed description

Intensive care units are specialized units where patients with multiple comorbidities are treated. The length of stay in intensive care varies according to the characteristics of the patient, the disease and the center. Prolonged intensive care stay causes an increase in mortality . It has been reported that the severity of the disease as well as the comorbidities of the patients contribute to prolonged stay . One third of patients with stay longer than seven days were evaluated as more fragile than before hospital admission. Prolonged intensive care length of stay leads to an increase in morbidity and mortality, bed demand and costs.

The Braden pressure ulcer scale was developed by Braden et al. in 1987 . Scoring is done under six different headings evaluating sensory perception, humidity, activity, mobility, nutrition and friction/cutting. It has been reported as an effective tool for evaluating pressure ulcer development in intensive care patients. In this scoring system, there are different assessment steps such as mobility, nutrition, sensory perception, etc., which allows the assessment of the functional capacity of the patients at the time of admission. In a study of elderly dementia patients, the Braden scale was found to be effective in predicting 90-day mortality. In a retrospective evaluation of patients with heart failure, the Braden scale was reported to predict 30-day mortality.

The aim of our study is to predict the length of intensive care stay by analyzing the Braden scales calculated on the day of hospitalization.

Keywords
Braden risk assesment scale, Length of stay, ICU

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT06697340
Study groupRoleWhat they receive
Group IIntensive Care patients admitted to tertiary intensive care unit and treated more than 24 hours

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Intensive care length of stay

    Patient intensive care length of stay

    Measured: Time period between patient admission to intensive care unit and patient discharge, patient transfer to ward or patient death, whichever came first. Estimated time up to 52 weeks

Secondary outcomes (1)
  1. Mortality

    All-cause mortality rate in the intensive care unit.

    Measured: Time interval between patient intensive care unit admission to patient mortality. Estimated time is up to 52 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 Nov 2024
  2. Study start1 Jan 2025
  3. Primary completion31 May 2025
  4. Study completion31 May 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Retrospective
Enrolment
11,000 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06697340
Sponsor's protocol ID
TABED 2-24-618
Acronym
BRILS
Status last verified
Jan 2025
First submitted
15 Nov 2024
Last updated
28 Jul 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Cheng H, Ling Y, Li Q, Tang Y, Li X, Liang X, Huang X, Su L, Lyu J. ICU admission Braden score independently predicts delirium in critically ill patients with ischemic stroke. Intensive Crit Care Nurs. 2024 Jun;82:103626. doi: 10.1016/j.iccn.2024.103626. Epub 2024 Jan 13.

    PubMed 38219301
  • Cheng H, Li X, Liang X, Tang Y, Wei F, Wang Z, Lyu J, Wang Y. Braden score can independently predict 90-day mortality in critically ill patients with dementia. Int J Geriatr Psychiatry. 2024 May;39(5):e6093. doi: 10.1002/gps.6093.

    PubMed 38752607
  • Bandle B, Ward K, Min SJ, Drake C, McIlvennan CK, Kao D, Wald HL. Can Braden Score Predict Outcomes for Hospitalized Heart Failure Patients? J Am Geriatr Soc. 2017 Jun;65(6):1328-1332. doi: 10.1111/jgs.14801. Epub 2017 Feb 21.

    PubMed 28221672

Questions about this trial

What is this clinical trial studying?

An observational study of Intensive Care Unit ICU and Length of ICU Stay, run by Ankara City Hospital Bilkent at 1 site in Turkey (Türkiye).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 28 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Intensive care length of stay (time frame: Time period between patient admission to intensive care unit and patient discharge, patient transfer to ward or patient death, whichever came first. Estimated time up to 52 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06697340, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Jul 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in